ANDOVER, Mass., and HAIFA, Israel – September 4, 2025 – MeMed, a leader in host-response diagnostics, announced today that several oral presentations at the upcoming American College of Emergency Physicians (ACEP) Scientific Assembly 2025 will showcase the growing body of clinical evidence supporting the utility of MeMed BV^®, its FDA-cleared test that distinguishes between bacterial and viral infections based on the body’s immune response.

The presentations span multiple leading U.S. medical centers and include real-world data, randomized controlled trial results, and new insights into MeMed BV’s role in supporting clinical decisions with challenging patient populations, such as immunocompromised individuals and the elderly. Collectively, these studies underscore MeMed BV’s potential to support decision-making in emergency departments (ED) and aid clinicians in their efforts to reduce unnecessary antibiotic use and unnecessary admissions, while lowering healthcare costs.

“Emergency physicians face intense pressure to make rapid, high-stakes decisions with incomplete information,” said Jason W. Wilson, Emergency Medicine Physician at Tampa General Hospital. “Data emerging at ACEP suggest that MeMed BV could be a valuable tool for clinicians when guiding care — especially in complex scenarios like suspected sepsis patients, where clinical uncertainty is highest.”

MeMed BV Data Presentations at ACEP 2025:

• Jason W. Wilson, MD, Tampa General Hospital — Preliminary data suggest that MeMed BV may provide clinical value to immunocompromised patients with suspected sepsis, a population wherein treatment decisions are particularly challenging.
• Alexandra LoVerde, MD, Maimonides Medical Center — A real-world study demonstrates how MeMed BV may have potentially influenced antibiotic prescription and hospital admission decisions, leading to improved patient flow in the ED.
• Adam J. Singer, MD, Stony Brook University and Principal Investigator, JUNO Trial — Results from the JUNO randomized controlled trial show MeMed BV’s role in supporting clinicians in their efforts to reduce antibiotic overuse, hospital admissions, and return visits, with potential cost savings of $706 per patient.
• Adam J. Singer, MD, Stony Brook University — Additional analyses on elderly patients with suspected urinary tract infections show how MeMed BV provided clinicians with valuable information to support more accurate diagnoses and treatment decisions.

In addition, Tom P. Aufderheide, MD, Medical College of Wisconsin, will be introducing new data on MeMed Severity™, a novel FDA Breakthrough Device-designated test that predicts severe outcomes in adults with suspected sepsis.

Building Market Momentum

MeMed BV is now in use at more than 150 sites, with over 100,000 patients tested to date. The company is progressing toward a milestone of one million patients tested. Growing adoption is supported by an expanding body of peer-reviewed publications and real-world studies that demonstrate both clinical value and economic benefit, reinforcing MeMed BV’s position as a novel test that could transform clinical decision-making in the ED.

* MeMed Severity is not yet cleared by regulatory authorities and is not for sale in any territory.